[A study of the oncolytic effect of a newly designed CDDP system on an experimental animal model with carcinomatous ascites].
We provided a novel cancer chemotherapeutic system for the treatment of locoregional cancer lesions, e.g. malignant peritonitis and pleuritis. The carriers were prepared with fibrin hydrogel clots (FCs) and hemostatic gelatin powder (Gp) using an original technique, after which cis-platinum (CDDP) was loaded into the carriers. In in vitro tests, the new carrier gradually degraded in 10-15 days in our fibrinolytic systems and the release of CDDP from the carrier continued for the same period. The CDDP delivered in the incubation medium was mainly the protein-bound type, and the released CDDP inhibited the proliferation of AH-130 ascitic hepatoma. To evaluate antineoplastic activities in vivo, we placed CDDP-loaded carriers into the abdominal cavities of AH-130 cancer-bearing rats. Seven of 8 cancer-bearing animals treated with our CDDP-systems survived for more than 5 weeks, and evidence of malignancy completely disappeared. These surviving rats were then challenged with AH-130 cells. Four of 5 repeatedly challenged rats survived for more than 7 months and revealed no evidence of recurrence of the cancer. All other rats died of cachexia with massive ascites and metastases within 2 weeks. Thus, our newly devised system exhibited a sustained release of CDDP with possible antineoplastic efficacy in an experimental animal model with carcinomatous ascites.